1. Secukinumab (Rheumatoid Arthritis) Forecast and Market
Analysis
Report Details:
Published:November 2012
No. of Pages: 45
Price: Single User License – US$6995
Secukinumab (Rheumatoid Arthritis) Forecast and Market Analysis
Summary
GlobalData has released its new PharmaPoint Drug Evaluation report, Secukinumab (Rheumatoid
Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the
November 6, 2012 FDA approval of Pfizer’s Xeljanz (tofacitinib) and novel oral therapies awaiting
approval such as: Eli Lilly’s anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ’s
SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to
dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once
they enter the market.
Novartis is developing a novel, subcutaneous, fully-human mAb IL-17A inhibitor, known as
secukinumab (or AIN457), which is in Phase III clinical trials in various countries including US, EU,
and Japan. It promotes inflammatory responses as it neutralizes IL-17A, resulting in the prevention
of bone loss. Secukinumab is currently in clinical development for RA as well as for Crohn’s
disease, MS, psoriatic arthritis, ankylosing spondylitis, and psoriasis.
Scope
- Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment
guidelines as well as an overview on the competitive landscape.
- Detailed information on Secukinumab including product description, safety and efficacy profiles
as well as a SWOT analysis.
- Sales forecast for Secukinumab for the top eight countries from 2011 to 2022.
- Sales information covered for the US, France, Germany, the UK, Italy, Spain, Japan and
Australia.
Reasons to buy

2. - Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for
rheumatoid arthritis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising
sales potential
- Make more informed business decisions from insightful and in-depth analysis of Secukinumab
performance
- Obtain sales forecast for Secukinumab from 2011 to 2022 in (the US, France, Germany, the UK,
Italy, Spain, Japan and Australia)
Get your copy of this report @
http://www.reportsnreports.com/reports/213180-secukinumab-rheumatoid-arthritis-forecast-and-market-
analysis.html
Major points covered in Table of Contents of this report include
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Introduction 6
2.1 Catalyst 6
2.2 Related Reports 7
3 Disease Overview 9
3.1 Etiology and Pathophysiology 9
3.1.1 Etiology 9
3.1.2 Pathophysiology 9
3.1.3 Prognosis 12
3.1.4 Quality of Life 12
3.2 Symptoms 13
4 Disease Management 14
4.1 Overview 14
4.2 Diagnosis 14
4.3 Treatment 16
5 Competitive Assessment 20
5.1 Overview 20
5.2 Strategic Competitor Assessment 20
6 Opportunity and Unmet Need 22
6.1 Overview 22
6.2 Unmet Needs 23
6.2.1 More rheumatologists in the field and physician knowledge of the disease 23
6.2.2 More cost-effective therapies through oral formulation and biosimilars 23
6.2.3 The development of predictive tests and discovery of biomarkers 24

3. 6.2.4 The discovery of curative therapies 24
6.2.5 Improved drug safety and efficacy profiles 24
6.3 Gap Analysis 25
6.4 Opportunities 26
6.4.1 Predictive tools for diagnosis and treatment 26
6.4.2 Target specificity 26
7 Pipeline Assessment 27
7.1 Overview 27
7.2 Promising Drugs in Clinical Development 28
8 Secukinumab (AIN457) 30
8.1 Overview 30
8.2 Efficacy 30
8.3 Safety 31
8.4 Dosing and Formulation 31
8.5 Potential Clinical Positioning 32
8.6 Potential Commercial Positioning 32
8.7 Pricing and Reimbursement 32
8.8 SWOT Analysis 32
8.9 Forecast 33
9 Appendix 34
9.1 Abbreviations 34
9.2 Bibliography 36
9.3 Methodology 39
9.4 Forecasting Methodology 39
9.4.1 Diagnosed Rheumatoid Arthritis Patients 39
9.4.2 Percent Drug-treated Patients 40
9.4.3 General Pricing Assumptions 40
9.4.4 Pricing of Pipeline agents 41
9.5 Physicians and Specialists Included in this Study 42
9.6 Primary Research - Prescriber Survey 42
9.7 About the Authors 43
9.7.1 Analysts 43
9.7.2 Global Head of Healthcare 44
9.8 About GlobalData 45
9.9 Contact Us 45
9.10 Disclaimer 45
1.1 List of Tables
Table 1: Symptoms of Rheumatoid Arthritis 13
Table 2: Treatment Guidelines for Rheumatoid Arthritis 17
Table 3: Top Three Biologics Prescribed for Moderate-Severe Rheumatoid Arthritis by Market 19
Table 4: Treatment Guidelines for Rheumatoid Arthritis 21

4. Table 5: Overall Unmet Needs - Current Level of Attainment 22
Table 6: Clinical Unmet Needs - Gap Analysis, 2012 26
Table 7: Rheumatoid Arthritis - Phase Pipeline, 2012 28
Table 8: Comparison of Therapeutic Classes in Development for RA, 2012 29
Table 9: Product Profile - Secukinumab 30
Table 10: Secondary Endpoint Results for Secukinumab vs. Placebo at Weeks 24 and 52 31
Table 11: Secukinumab SWOT Analysis, 2012 32
Table 12: Global Sales Forecasts ($m) for Secukinumab 33
Table 13: Physicians Surveyed, By Country 42
1.2 List of Figures
Figure 1: Healthy and Arthritic Joint with Rheumatoid Arthritis 9
Figure 2: Rheumatoid Arthritis Biologic Drug Targets 11
Figure 3: Diagnosis Criteria for Rheumatoid Arthritis Based on 2010 ACR/EULAR Criteria Point
System 15
Figure 4: Severity of Rheumatoid Arthritis 16
Figure 5: Biologic Treatment Flow Based on Updated 2012 ACR Treatment Recommendations*
18
Figure 6: Competitive Assessment of Late-Stage Pipeline Agents in RA, 2012-2022 28
Contact: sales@reportsandreports.com for more information.